Mauna Kea Technologies SA (MKEAF)
- Business Wire
On Target Laboratories and Mauna Kea Technologies Demonstrate Intraprocedural Targeted Detection of Lung Cancer with a Molecular Imaging Agent
WEST LAFAYETTE, Ind. & PARIS & BOSTON, May 18, 2022--Regulatory News: On Target Laboratories, Inc. (‘On Target’) a privately-held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery and Mauna Kea Technologies (Euronext: MKEA, ‘Mauna Kea’) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced publication of a study entitled "Targeted Detection of Canc
- Business Wire
Mauna Kea Technologies Publishes Q1 2022 Sales and Its 2021 Financial Results
PARIS & BOSTON, April 21, 2022--Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multidisciplinary probe and needle confocal laser endomicroscopy (p/nCLE) platform, today announced financial results (unaudited) for the year ended December 31, 2021, and its sales for the first quarter ended March 31, 20221.
- GlobeNewswire
Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
Dose increase of R327 Dose increase of R327 Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee affirms ‘low-dose’ cohort clinical trial complete, endpoints achieved – recommends ‘high dose’ cohort dosing to beginCommittee clears cohort five (R327 – 2,000mg IV) dosing – subjects recruited and dosing underway SYDNEY, Australia, April 13, 2022 (GLOBE NEWSWIRE)
